We examined the efficacy and host response to the adenovirus (Ad)-mediated delivery of human apolipoprotein A-I (APOA1) gene to the liver of APOA1−/− mice. Administration of a first-generation vector (FGAd-AI) resulted in a transient appearance of APOA1 in plasma and induced an anti-APOA1 antibody titer, whereas treatment with a helper-dependent vector (HDAd-AI) resulted in sustained APOA1 expression without inducing an antibody titer. With these results, we studied the effects of FGAd vectors on APOAI expression by HDAd-AI vector. Co-treatment with an FGAd vector inhibited HDAd-AI- mediated APOA1 expression independent of transgene cassettes, but only FGAd-AI induced a humoral response. Furthermore, APOA1 mRNA levels in mice co-treated with FGAd vectors were much lower than those expected from the vector copy number, suggesting that DNA of FGAd vectors interferes with the HDAd-AI vector's APOA1 promoter. A single treatment with an HDAd-AI vector produced a supraphysiological plasma APOA1 level that gradually declined to about half the normal human level over the course of 2 years, associated with a plasma cholesterol level that is persistently higher than that in controls. This investigation provides the proof of principle that liver-directed HDAd gene delivery is effective for the long-term phenotypic correction of monogenic hypoalphalipoproteinemia.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Schaefer EJ, Lamon-Fava S, Ordovas JM, Cohn SD, Schaefer MM, Castelli WP et al. Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study. J Lipid Res 1994; 35: 871–882.
Kannel WB . Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol 1995; 76: 69C–77C.
Gordon DJ, Rifkind BM . High-density lipoprotein – the clinical implications of recent studies. N Engl J Med 1989; 321: 1311–1316.
Maciejko JJ, Holmes DR, Kottke BA, Zinsmeister AR, Dinh DM, Mao SJ . Apolipoprotein A-I as a marker of angiographically assessed coronary-artery disease. N Engl J Med 1983; 309: 385–389.
Schaefer EJ, Heaton WH, Wetzel MG, Brewer Jr HB . Plasma apolipoprotein A-1 absence associated with a marked reduction of high density lipoproteins and premature coronary artery disease. Arteriosclerosis 1982; 2: 16–26.
Forte TM, Nichols AV, Krauss RM, Norum RA . Familial apolipoprotein AI and apolipoprotein CIII deficiency. Subclass distribution, composition, and morphology of lipoproteins in a disorder associated with premature atherosclerosis. J Clin Invest 1984; 74: 1601–1613.
Yamakawa-Kobayashi K, Yanagi H, Fukayama H, Hirano C, Shimakura Y, Yamamoto N et al. Frequent occurrence of hypoalphalipoproteinemia due to mutant apolipoprotein A-I gene in the population: a population-based survey. Hum Mol Genet 1999; 8: 331–336.
Schiedner G, Morral N, Parks RJ, Wu Y, Koopmans SC, Langston C et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet 1998; 18: 180–183.
Morral N, O'Neal W, Rice K, Leland M, Kaplan J, Piedra PA et al. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci USA 1999; 96: 12816–12821.
Oka K, Pastore L, Kim IH, Merched A, Nomura S, Lee HJ et al. Long-term stable correction of low-density lipoprotein receptor-deficient mice with a helper-dependent adenoviral vector expressing the very low-density lipoprotein receptor. Circulation 2001; 103: 1274–1281.
Kim IH, Jozkowicz A, Piedra PA, Oka K, Chan L . Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci USA 2001; 98: 13282–13287.
Belalcazar LM, Merched A, Carr B, Oka K, Chen KH, Pastore L et al. Long-term stable expression of human apolipoprotein A-I mediated by helper-dependent adenovirus gene transfer inhibits atherosclerosis progression and remodels atherosclerotic plaques in a mouse model of familial hypercholesterolemia. Circulation 2003; 107: 2726–2732.
Brunetti-Pierri N, Nichols TC, McCorquodale S, Merricks E, Palmer DJ, Beaudet AL et al. Sustained phenotypic correction of canine hemophilia B after systemic administration of helper-dependent adenoviral vector. Hum Gene Ther 2005; 16: 811–820.
Toietta G, Mane VP, Norona WS, Finegold MJ, Ng P, McDonagh AF et al. Lifelong elimination of hyperbilirubinemia in the Gunn rat with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci USA 2005; 102: 3930–3935.
Nomura S, Merched A, Nour E, Dieker C, Oka K, Chan L . Low-density lipoprotein receptor gene therapy using helper-dependent adenovirus produces long-term protection against atherosclerosis in a mouse model of familial hypercholesterolemia. Gene Therapy 2004; 11: 1540–1548.
De Geest B, Zhao Z, Collen D, Holvoet P . Effects of adenovirus-mediated human apo A-I gene transfer on neointima formation after endothelial denudation in apo E-deficient mice. Circulation 1997; 96: 4349–4356.
Raper SE, Yudkoff M, Chirmule N, Gao GP, Nunes F, Haskal ZJ et al. A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum Gene Ther 2002; 13: 163–175.
O'Neal WK, Zhou H, Morral N, Aguilar-Cordova E, Pestaner J, Langston C et al. Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing alpha1-antitrypsin after systemic delivery. Hum Gene Ther 1998; 9: 1587–1598.
Morral N, O'Neal WK, Rice K, Leland MM, Piedra PA, Aguilar-Cordova E et al. Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons. Hum Gene Ther 2002; 13: 143–154.
Brunetti-Pierri N, Palmer DJ, Beaudet AL, Carey KD, Finegold M, Ng P . Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum Gene Ther 2004; 15: 35–46.
Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM . Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407–4411.
Higginbotham JN, Seth P, Blaese RM, Ramsey WJ . The release of inflammatory cytokines from human peripheral blood mononuclear cells in vitro following exposure to adenovirus variants and capsid. Hum Gene Ther 2002; 13: 129–141.
Tatsis N, Ertl HC . Adenoviruses as vaccine vectors. Mol Ther 2004; 10: 616–629.
Kelly ME, Clay MA, Mistry MJ, Hsieh-Li HM, Harmony JA . Apolipoprotein E inhibition of proliferation of mitogen-activated T lymphocytes: production of interleukin 2 with reduced biological activity. Cell Immunol 1994; 159: 124–139.
van den Elzen P, Garg S, Leon L, Brigl M, Leadbetter EA, Gumperz JE et al. Apolipoprotein-mediated pathways of lipid antigen presentation. Nature 2005; 437: 906–910.
Kozarsky KF, Jooss K, Donahee M, Strauss 3rd JF, Wilson JM . Effective treatment of familial hypercholesterolaemia in the mouse model using adenovirus-mediated transfer of the VLDL receptor gene. Nat Genet 1996; 13: 54–62.
Plump AS, Azrolan N, Odaka H, Wu L, Jiang X, Tall A et al. ApoA-I knockout mice: characterization of HDL metabolism in homozygotes and identification of a post-RNA mechanism of apoA-I up-regulation in heterozygotes. J Lipid Res 1997; 38: 1033–1047.
Toietta G, Pastore L, Cerullo V, Finegold M, Beaudet AL, Lee B . Generation of helper-dependent adenoviral vectors by homologous recombination. Mol Ther 2002; 5: 204–210.
Wolins N, Lozier J, Eggerman TL, Jones E, Aguilar-Cordova E, Vostal JG . Intravenous administration of replication-incompetent adenovirus to rhesus monkeys induces thrombocytopenia by increasing in vivo platelet clearance. Br J Haematol 2003; 123: 903–905.
Eggerman TL, Mondoro TH, Lozier JN, Vostal JG . Adenoviral vectors do not induce, inhibit, or potentiate human platelet aggregation. Hum Gene Ther 2002; 13: 125–128.
Lozier JN, Csako G, Mondoro TH, Krizek DM, Metzger ME, Costello R et al. Toxicity of a first-generation adenoviral vector in rhesus macaques. Hum Gene Ther 2002; 13: 113–124.
Morral N, Parks RJ, Zhou H, Langston C, Schiedner G, Quinones J et al. High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity. Hum Gene Ther 1998; 9: 2709–2716.
Bristol JA, Shirley P, Idamakanti N, Kaleko M, Connelly S . In vivo dose threshold effect of adenovirus-mediated factor VIII gene therapy in hemophiliac mice. Mol Ther 2000; 2: 223–232.
Ziegler RJ, Li C, Cherry M, Zhu Y, Hempel D, van Rooijen N et al. Correction of the nonlinear dose response improves the viability of adenoviral vectors for gene therapy of Fabry disease. Hum Gene Ther 2002; 13: 935–945.
Tao N, Gao GP, Parr M, Johnston J, Baradet T, Wilson JM et al. Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther 2001; 3: 28–35.
Zhang Y, Chirmule N, Gao GP, Qian R, Croyle M, Joshi B et al. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol Ther 2001; 3: 697–707.
Schiedner G, Hertel S, Johnston M, Dries V, van Rooijen N, Kochanek S . Selective depletion or blockade of Kupffer cells leads to enhanced and prolonged hepatic transgene expression using high-capacity adenoviral vectors. Mol Ther 2003; 7: 35–43.
Fields PA, Armstrong E, Hagstrom JN, Arruda VR, Murphy ML, Farrell JP et al. Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice. Gene Therapy 2001; 8: 354–361.
Kung SH, Hagstrom JN, Cass D, Tai SJ, Lin HF, Stafford DW et al. Human factor IX corrects the bleeding diathesis of mice with hemophilia B. Blood 1998; 91: 784–790.
Muruve DA, Cotter MJ, Zaiss AK, White LR, Liu Q, Chan T et al. Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo. J Virol 2004; 78: 5966–5972.
De Geest BR, Van Linthout SA, Collen D . Humoral immune response in mice against a circulating antigen induced by adenoviral transfer is strictly dependent on expression in antigen-presenting cells. Blood 2003; 101: 2551–2556.
De Geest B, Van Linthout S, Lox M, Collen D, Holvoet P . Sustained expression of human apolipoprotein A-I after adenoviral gene transfer in C57BL/6 mice: role of apolipoprotein A-I promoter, apolipoprotein A-I introns, and human apolipoprotein E enhancer. Hum Gene Ther 2000; 11: 101–112.
De Geest B, Van Linthout S, Collen D . Sustained expression of human apo A-I following adenoviral gene transfer in mice. Gene Therapy 2001; 8: 121–127.
Pastore L, Morral N, Zhou H, Garcia R, Parks RJ, Kochanek S et al. Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors. Hum Gene Ther 1999; 10: 1773–1781.
Dudley RW, Lu Y, Gilbert R, Matecki S, Nalbantoglu J, Petrof BJ et al. Sustained improvement of muscle function one year after full-length dystrophin gene transfer into mdx mice by a gutted helper-dependent adenoviral vector. Hum Gene Ther 2004; 15: 145–156.
Chen ZY, He CY, Meuse L, Kay MA . Silencing of episomal transgene expression by plasmid bacterial DNA elements in vivo. Gene Therapy 2004; 11: 856–864.
Ehrhardt A, Xu H, Huang Z, Engler JA, Kay MA . A direct comparison of two nonviral gene therapy vectors for somatic integration: in vivo evaluation of the bacteriophage integrase phiC31 and the Sleeping Beauty transposase. Mol Ther 2005; 11: 695–706.
Polansky H . Microcompetition with Foreign DNA and the Origin of Chronic Disease. The Center for the Biology and Chronic Disease: Rochester, 2003.
Wen S, Graf S, Massey PG, Dichek DA . Improved vascular gene transfer with a helper-dependent adenoviral vector. Circulation 2004; 110: 1484–1491.
Harui A, Suzuki S, Kochanek S, Mitani K . Frequency and stability of chromosomal integration of adenovirus vectors. J Virol 1999; 73: 6141–6146.
Hillgenberg M, Tonnies H, Strauss M . Chromosomal integration pattern of a helper-dependent minimal adenovirus vector with a selectable marker inserted into a 27.4-kilobase genomic stuffer. J Virol 2001; 75: 9896–9908.
Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL . A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA 1996; 93: 13565–13570.
Kobayashi K, Oka K, Forte T, Ishida B, Teng B, Ishimura-Oka K et al. Reversal of hypercholesterolemia in low density lipoprotein receptor knockout mice by adenovirus-mediated gene transfer of the very low density lipoprotein receptor. J Biol Chem 1996; 271: 6852–6860.
Sandig V, Youil R, Bett AJ, Franlin LL, Oshima M, Maione D et al. Optimization of the helper-dependent adenovirus system for production and potency in vivo. Proc Natl Acad Sci USA 2000; 97: 1002–1007.
Kreppel F, Biermann V, Kochanek S, Schiedner G . A DNA-based method to assay total and infectious particle contents and helper virus contamination in high-capacity adenoviral vector preparations. Hum Gene Ther 2002; 13: 1151–1156.
This work was supported by HL59314 and HL73144. A Paul was supported by the grant from American Heart Association (0535118N). We thank A Beaudet for valuable discussion; S Kochanek and G Shiedner for providing 293Cre66 cells; J Smith for APOE gene; F Graham for providing helper virus; Merck & Co. for providing reagents developed by F Graham.
Rights and permissions
About this article
Cite this article
Oka, K., Belalcazar, L., Dieker, C. et al. Sustained phenotypic correction in a mouse model of hypoalphalipoproteinemia with a helper-dependent adenovirus vector. Gene Ther 14, 191–202 (2007). https://doi.org/10.1038/sj.gt.3302819
- helper-dependent adenovirus
- apolipoprotein A-I
- adaptive immunity
This article is cited by
Helper-dependent adenovirus achieve more efficient and persistent liver transgene expression in non-human primates under immunosuppression
Gene Therapy (2015)
Study of the Efficacy, Biodistribution, and Safety Profile of Therapeutic Gutless Adenovirus Vectors as a Prelude to a Phase I Clinical Trial for Glioblastoma
Clinical Pharmacology & Therapeutics (2010)
A rapid protocol for construction and production of high-capacity adenoviral vectors
Nature Protocols (2009)
Gene Therapy for Diabetes: Metabolic Effects of Helper-dependent Adenoviral Exendin 4 Expression in a Diet-induced Obesity Mouse Model
Molecular Therapy (2008)